MedTrace Logo

Circadian Thermal Sensing to Detect Breast Disease

NCT02511301 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2019-01-03

No results posted yet for this study

Summary

The purpose of this study is to determine if Cyrcadia's Circadian Biometric Recorder (CBR™), which is attached to soft biometric patches worn on the body, can improve early breast cancer detection along with mammography or as a stand alone device.

Conditions

  • Early-Stage Breast Carcinoma

Interventions

DEVICE

Cyrcadia CBR™ device placement for abnormality screening

Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.

Sponsors & Collaborators

  • Stanford University

    collaborator OTHER

  • Salesforce

    collaborator UNKNOWN

  • Ohio State University

    collaborator OTHER

  • Cyrcadia Health

    lead INDUSTRY

Principal Investigators

  • Joshua Ellenhorn, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511301 on ClinicalTrials.gov